Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

2/23/2015 Hemispherx Biopharma: Institute of Medicine, the Health Arm of the US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) as a “Systemic Exertion Intolerance Disease” (SEID)

2/12/2015 Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen® Against the Ebola Virus at Upcoming International Symposium on Filoviruses
…..Ampligen® May Be an Important Candidate for EBOV Testing in West Africa


2/9/2015 Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen® Produced 100% Survival Rate in Rodents with 100% mortality in placebo.
Hemispherx Challenges False Accusations in Recent Online and Social Media Postings


2/2/2015 Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen® Produces 100% Survival Rate in Ebola Virus Rodent Study
……Placebo Group had a 100% Death Rate


1/26/2015 USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
……Hemispherx’s Experimental Biotherapeutics May Escape Mutational Impediments


More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com